

A VALIDATED HPLC METHOD FOR ESTIMATION OF METOPROLOL IN HUMAN PLASMA

M. Aqil^{1,}, A. Ali¹, A. Ahad¹, Y. Sultana¹, A. K. Najmi¹, and N. Saha²*

¹Faculty of Pharmacy, Hamdard University New Delhi, 110 062, India

²Ranbaxy Clinical Pharmacology Unit, Majeedia Hospital, New Delhi 110 062, India

SUMMARY

A high-performance reversed-phase liquid chromatographic method for quantification of metoprolol tartrate (MT) in human plasma is presented. A C₁₈ column was used with acetonitrile–water–triethylamine 18:81:1 (v/v) as mobile phase and pinacidil monohydrate as internal standard (IS). UV detection was at 275 nm and MT and the IS were detected at retention times of 1.5 and 2.6 min, respectively. The method is sensitive with a limit of quantification of 20 ng mL⁻¹. The calibration plot for MT in spiked plasma was linear in the concentration range 20–200 ng mL⁻¹. Within-batch and total accuracy of the method ranged between 99.71% and 101.61%, and within-batch and total precision, expressed as the coefficient of variation, was 0.20–2.13%. Recovery of MT from spiked plasma was 97.00% and the freeze–thaw and bench-top stability of samples ranged from 77.92 to 105.62%. The method can be successfully used for analysis of MT in human plasma during pharmacokinetic studies.

INTRODUCTION

Metoprolol tartrate (MT) is an established selective β_1 -blocking drug used for management of moderate to severe essential hypertension [1]. Many dosage forms of MT are available commercially, including tablets. Because the drug undergoes hepatic first-pass metabolism in the body, leading to low oral bioavailability, a transdermal drug-delivery system has been developed to circumvent the problem. This work is part of clinical studies performed to ascertain the comparative bioavailability of MT from oral and transdermal dosage forms.

Several methods have been reported for quantification of MT in plasma using high-performance liquid chromatography (HPLC) with UV

or fluorescence detection [2–14]. Many of these methods involve a complex separation step and are non-reproducible. This paper reports a simple, rapid, sensitive, and reproducible method for analysis of MT in plasma, using pinacidil monohydrate as internal standard (IS). The method was validated for accuracy, precision, linearity, sensitivity, and stability.

EXPERIMENTAL

Chemicals and Reagents

Metoprolol tartrate MT (Fig. 1) was a gift from Astra-IDL, India. Pinacidil monohydrate PM was obtained from Leo Pharmaceuticals, Denmark. HPLC-grade acetonitrile and water were from Merck, India. All other chemicals and solvents were HPLC or AR-grade and were used as received.




Fig. 1

The chemical structure of metoprolol tartrate

MT working standard (5 mg) was accurately weighed, transferred to a 50-mL volumetric flask, and diluted to volume with the mobile phase to produce a stock solution containing $100 \mu\text{g mL}^{-1}$.

A solution of PM, the internal standard (IS), was prepared by dissolving 5 mg PM in mobile phase in a 50-mL volumetric flask and diluting to volume with the mobile phase to furnish a stock solution containing $100 \mu\text{g mL}^{-1}$. For spiking plasma samples this stock solution was diluted to $2 \mu\text{g mL}^{-1}$ with water.

Chromatography

HPLC was performed with a Shimadzu (Japan) SCL10AT system comprising an LC-10 AT pump, an autosampler, and an SPD-10A detec-

tor. Data processing was by Shimadzu Class-VP software on a Hewlett–Packard computer. Compounds were separated on a 250 mm × 4 mm, 10- μ m particle, Novapack C-18 column.

Before method development, column performance was tested by duplicate injection of a mixture of resorcinol, naphthalene, and anthracene (10 μ L) with acetonitrile–water 55:45 as mobile phase at a flow rate of 1.0 mL min⁻¹. Detection was by UV absorption at 254 nm. System suitability was then tested by injecting a dilute solution of drug five times using the same chromatographic conditions.

The mobile phase used for the method was acetonitrile–water–triethylamine 18:81:1 (*v/v*), pH adjusted to 11 by use of phosphoric acid; before use the mobile phase was degassed and filtered through a 0.45- μ m filter. The flow rate was 1.0 mL min⁻¹ and MT was detected by UV absorption at 275 nm.

Calibration

Serial dilutions (1–10 μ g mL⁻¹) of the MT stock solution were prepared in the mobile phase. Each of these dilutions (1 mL) was added to 49 mL screened plasma, to furnish concentrations in the range 20–200 ng mL⁻¹. These samples were analysed by HPLC and the areas of the MT peak were plotted against the concentration of MT. The calibration data obtained are listed in Table I and the calibration plot constructed from the data is shown in Fig. 2.

Table I

Calibration data for metoprolol tartrate in water–acetonitrile–triethylamine 81:18:1 (*v/v*) after spiking of plasma with stock solutions

No.	Drug concentration in spiked plasma (ng mL ⁻¹), <i>X</i>	Peak area ^a	Regressed value of peak area, <i>Y</i>	<i>SD</i>
1	20	154694	165856	3218
2	40	298620	303284	2873
3	80	596181	578141	1528
4	120	865487	852997	4384
5	160	1117645	1127853	3024
6	200	1398217	1402710	5387

^a*n* = 5, i.e. results are means from five observations




Fig. 2

Calibration plot for metoprolol tartrate in water–acetonitrile–triethylamine 81:18:1 (v/v) after spiking of plasma with the pure drug. Regression equation, $Y = 6871X + 28428$, correlation coefficient, r , 0.9997

Method Validation

The method was validated for accuracy, precision, sensitivity, recovery, linearity, and stability in accordance with ICH guidelines [15], using PM as IS. Linearity, precision, and accuracy were tested by analysis of five batches of spiked plasma quality-control (QC) samples. Each batch of spiked plasma samples included one complete set of calibration standards (comprising six different concentrations, blank, and blank with internal standard) and QC samples at low (40 ng mL⁻¹, LQC), middle (70 ng mL⁻¹, MQC), and high (100 ng mL⁻¹, HQC) concentrations.

Linearity was determined by regression analysis of the calibration data and determination of the coefficient of variation. Sensitivity was determined as the limits of detection (*LOD*) and quantification (*LOQ*). The accuracy of the method was evaluated as the MT-to-IS peak-area ratio. Precision was measured as the coefficient of variation (%) for the low, middle, and high QC samples during validation. Recovery (%) was determined by measuring the MT-to-IS peak-area ratio for the plasma QC samples (LQC, MQC, and HQC) with the MT-to-IS peak-area ratios of freshly prepared unextracted aqueous standards containing the same concentrations of MT. To determine the freeze–thaw stability of spiked plasma samples five replicates each of the low, middle, and high QC samples were analyzed after one and two freeze–thaw cycles. The freeze–thaw QC samples were

quantified by comparison with a calibration plot prepared after chromatography of freshly spiked samples. For assessment of bench-top stability, the concentrations of low, middle, and high QC samples were determined after 0, 2, and 4 h. The MT-to-IS peak-area response ratios after 2 and 4 h were compared with that after 0 h.

RESULTS AND DISCUSSION

Under these chromatographic conditions MT and IS in a plasma matrix were resolved with retention times (t_R) of 1.5 and 2.6 min, respectively. The method was found to be suitable because reproducible results were obtained on each sample run. On validation of the above method using PM as the IS, the following results were obtained.

Linearity

The linearity of the calibration plot for MT in human plasma at concentrations 20, 40, 80, 120, 160, and 200 ng mL⁻¹ was excellent




Fig. 3

Representative chromatogram obtained during quantification of metoprolol tartrate ($t_R = 1.5$ min) in human plasma with pinacidil monohydrate ($t_R = 2.6$ min) as IS

($r = 0.9997$) over the concentration range investigated. A typical calibration plot obtained during plasma analysis could be described by the linear equation, $Y = 6871X + 28428$, where Y is peak area and X is concentration (ng mL^{-1}). Five calibration plots were constructed; the results obtained are presented in Table I and Figs 2 and 3.

Sensitivity

The limits of detection (LOD) and quantification (LOQ) for metoprolol tartrate were calculated by use of the formulae $LOD = 3.3\sigma/S$ and $LOQ = 10\sigma/S$, where σ is the standard deviation of the response and S is the slope of the calibration plot. For analysis of 1 mL spiked plasma the LOD was 5 ng mL^{-1} and the LOQ 20 ng mL^{-1} .

Accuracy

The within-batch accuracy, determined by use of the internal standard area-ratio method, ranged from 99.71 to 101.61% (Table II). The between-batch or total accuracy, determined by use of the internal standard area-ratio method, was found to be 99.91 to 100.60% (Table II).

Table II

Within and between-batch precision and accuracy for analysis of metoprolol tartrate

Actual	Nominal concentration (ng mL^{-1})		
	LQC ^a ,	MQC ^a ,	HQC ^a ,
	40.4721	70.5232	100.7328
QC1	40.3625	70.8324	100.3467
QC2	40.6823	70.5983	100.5675
QC3	39.9847	71.7345	100.8635
QC4	41.2839	69.2384	99.9928
Mean	40.5783	70.6009	100.4426
<i>SD</i>	0.5500	1.032	0.3671
<i>CV</i> (%)	1.35	1.46	0.36
Nominal (%)	100.26	100.01	99.71
QC5	40.4683	70.9395	100.9338
QC6	39.8341	69.7682	99.9853
QC7	40.7375	70.7555	100.752
QC8	41.8382	70.3248	100.3253
Mean	40.7195	70.4470	100.4992
<i>SD</i>	0.8364	0.5207	0.4271
<i>CV</i> (%)	2.05	0.74	0.42
Nominal (%)	100.61	99.89	99.77

Table II (continued)

Within and between-batch precision and accuracy for analysis of metoprolol tartrate

	Nominal concentration (ng mL ⁻¹)		
QC9	40.5354	70.6848	100.9461
QC10	40.8252	69.5347	100.7877
QC11	39.8411	70.3548	100.8089
QC12	40.7231	71.4039	100.4040
Mean	40.4812	70.4945	100.7366
<i>SD</i>	0.3839	0.6715	0.2015
<i>CV</i> (%)	0.95	0.95	0.20
Nominal (%)	100.02	99.96	100.00
QC13	40.1001	70.3845	101.3801
QC14	39.9387	69.9128	100.9821
QC15	41.8177	70.6599	100.5347
QC16	40.9462	70.6848	100.7081
Mean	40.7007	70.4105	100.9013
<i>SD</i>	0.8659	0.3586	0.3685
<i>CV</i> (%)	2.13	0.51	0.36
Nominal (%)	100.56	99.84	100.17
QC17	40.4076	71.9123	100.5157
QC18	41.5347	70.8652	101.3738
QC19	40.9995	69.3920	100.6598
QC20	41.4696	70.5830	99.9991
Mean	41.1028	70.6881	100.6371
<i>SD</i>	0.5212	1.0362	0.5672
<i>CV</i> (%)	1.27	1.46	0.56
Nominal (%)	101.56	100.23	99.90
	Total global statistics		
Actual	LQC, 40.4721	MQC, 70.5232	HQC, 100.7328
Mean	40.7165	70.5282	100.6434
<i>SD</i>	0.6147	0.7119	0.3994
<i>CV</i> (%)	1.51	1.01	0.40
Nominal (%)	100.60	100.00	99.91

^aLQC, low quality control; MQC, middle quality control; HQC, high quality control**Precision**

Within-batch precision, determined by use of the internal standard area-ratio method, ranged from 0.20 to 2.13% (Table II). The between-batch

or total precision, determined by use of internal standard area ratio method, ranged from 0.40 to 1.15% (Table II).

Recovery

Recovery (%) was determined by comparing the MT-to-IS peak-area ratio for the plasma QC samples (LQC, MQC, and HQC) with the MT-to-IS peak-area ratio for freshly prepared unextracted aqueous standards containing the same concentrations of MT. Total recovery of metoprolol tartrate was 93.95% and within batch recovery was 91.59 to 97.00% (Table III).

Table III

Absolute recovery of metoprolol tartrate from human plasma

QC	Individual % recovery			Total recovery (%)
	LQC	MQC	HQC	
1	91.5345	95.7266	97.4632	
2	99.6366	88.7573	94.3177	
3	90.3233	95.4163	94.7687	
4	87.4822	90.5341	98.9154	
5	88.9958	95.9528	99.5640	
Mean	91.5945	95.2774	97.0058	93.9592
<i>SD</i>	4.7423	2.9701	2.3786	4.0968
<i>CV</i> (%)	5.18	3.18	2.45	4.36
<i>n</i>	5	5	5	15

Stability

The freeze–thaw stability ranged from 77.92 to 103.02%. The stability through one and two freeze–thaw cycles was from 85.06 to 103.02% and from 77.92% to 89.76%, respectively. The freeze–thaw stability of MT over two cycles was therefore acceptable (Table IV). To meet acceptance criteria MT must be stable in plasma samples for up to 4 h. The bench-top stability ranged between 88.74 to 105.62% (Table V).

The results from method validation are summarised in Table VI. The method was used for quantification of MT in plasma to investigate comparative bioavailability after administration of the drug by the oral and transdermal routes [16]. Experimental values of pharmacokinetic data after oral administration were comparable with literature data [1].

Table IV

Freeze–thaw stability of metoprolol tartrate in human plasma

	Individual stability (%)		
	LQC	MQC	HQC
One cycle			
1	91.3628	99.8230	99.7645
2	78.7324	95.1231	103.2015
3	83.7189	97.3842	110.3246
4	86.4112	89.5673	98.7843
Mean	85.0563	95.4744	103.0187
<i>SD</i>	4.56	3.79	4.5257
<i>CV</i> (%)	5.37	3.97	4.39
<i>n</i>	4	4	4
Two cycles			
1	85.1245	86.7321	91.8005
2	73.1911	88.2345	93.1295
3	72.8612	82.2265	88.8056
4	80.5162	79.3082	85.3098
Mean	77.9232	84.1253	89.7613
<i>SD</i>	5.1623	3.5528	3.0097
<i>CV</i> (%)	6.62	4.22	3.35
<i>n</i>	4	4	4

Table V

Bench-top stability of metoprolol in human plasma

Time (h)	% Initial		
	LQC	MQC	HQC
0	100.00	100.00	100.00
2	99.71	105.62	88.74
4	101.57	92.75	103.64
<i>n</i>	3	3	3

CONCLUSION

A simple, rapid, reproducible, and sensitive HPLC method has been developed for analysis of MT in human plasma. The short chromatographic run time of only 1.5 min makes this method suitable for processing of ma-

Table VI

Summary of results from method validation

Method characteristic	Result
Analyte	Metoprolol tartrate
Biological Matrix	Human plasma
Detection	UV, 275 nm
Retention time (min)	
MT	1.5
IS	2.6
Linear range (ng mL ⁻¹)	20–200
Limit of quantification (ng mL ⁻¹)	20
Limit of detection (ng mL ⁻¹)	5
Accuracy (%)	
Within batch	99.71 to 101.61
Total	99.91 to 100.60
Precision (%)	
Within batch	0.20 to 2.13
Total	0.40 to 1.51
Recovery (%)	
Within batch	91.59 to 97.00
Total	93.95
Stability (%)	
Freeze–thaw (1 cycle)	85.06 to 103.02
Freeze–thaw (2 cycles)	77.92 to 89.76
Bench-top	88.74 to 105.62

Validation was performed in accordance with ICH guidelines [15]

ny samples in limited time for pharmacokinetic and bioequivalence studies. The method was validated for analysis of MT in human plasma over the range 20 to 200 ng mL⁻¹.

ACKNOWLEDGEMENTS

The authors are grateful to Ranbaxy Clinical Pharmacology Unit, Majeedia Hospital, Hamdard University, New Delhi for providing facilities for this work.

REFERENCES

- [1] C. Dollery, *Therapeutic Drugs*, Churchill Livingstone, New York, 1991
- [2] M.M. Bhatti and R.T. Foster, *J. Chromatogr.*, **579**, 361 (1992)
- [3] V.L. Herring, T.L. Bastian, and R.L. Lolende, *J. Chromatogr.*, **567**, 221 (1991)
- [4] S. Uzu, K. Imai, K. Nakashima, and S. Akiyama, *Analyst*, **116**, 1353 (1991)
- [5] R.J. Straka, K.A. Johnson, P.S. Marshall, and R.P. Rimmel, *J. Chromatogr.*, **530**, 89 (1990)
- [6] J. Hermansson and C. von Bahr, *J. Chromatogr.*, **227**, 113 (1982)
- [7] Y. Horai, T. Ishizaki, M. Kusaka, G. Tsujimoto, and K. Hashimoto, *Ther. Drug Monit.*, **10**, 428 (1988)
- [8] K. Balmer, P.O. Alagerstrom, B.A. Persson, and G. Schill, *J. Chromatogr.*, **553**, 391 (1991)
- [9] J. Shen, C.T. Hung, and A.R. Zoest, *J. Liq. Chromatogr.*, **14**, 777 (1991)
- [10] D. Scuster, M.W. Modi, D. Lalka, and F.M. Gengo, *J. Chromatogr.*, **433**, 318 (1988)
- [11] D.R. Rutledge and C. Garrick, *J. Chromatogr. Sci.*, **27**, 561 (1989)
- [12] V.L. Lanchote, P.S. Bonato, P.M. Cerqueira, V.A. Pereira, and E.J. Cesarino, *Biomed. Sci. Appl.*, **738**, 27 (2000)
- [13] A.J. Braza, P. Modamio, C.F. Lastra, and E.L. Marino, *Biomed. Chromatogr.*, **16**, 517 (2002)
- [14] P.M. Cerqueira, E.J. Cesarino, C. Bertucci, P.S. Bonato, and V.L. Lanchote, *Chirality*, **15**, 542 (2003)
- [15] International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, *Validation of Analytical Procedures: methodology*, adopted in 1996, Geneva
- [16] M. Aqil, Ph.D. Thesis, Hamdard University, New Delhi, 2001